Krystal Biotech initiated with a Buy at H.C. Wainwright. H.C. Wainwright analyst Joseph Pantginis started Krystal Biotech with a Buy rating and $32 price target. The analyst believes the company has the potential to become a leader in the gene therapy space for the treatment of dermatological diseases.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.